Blueprint Medicines Corporation
BPMC
주식 순위
#2365
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
주가
$129.46
마지막 동기화: 2025-07-18
시가총액
$8.36B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Blueprint Medicines Corporation (BPMC)
카테고리
Healthcare
Blueprint Medicines Corporation (BPMC)의 P/E 비율
October 2026 기준 P/E 비율 TTM: -120.99
Blueprint Medicines Corporation의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 -120.99입니다. 2023년 말 기준 P/E 비율은 -11.02였습니다.
Blueprint Medicines Corporation의 P/E 비율 기록 (2013 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | -120.99 | 48.06% |
| 2024 | -81.72 | 641.69% |
| 2023 | -11.02 | 135.09% |
| 2022 | -4.69 | -51.84% |
| 2021 | -9.73 | -149.94% |
| 2020 | 19.49 | -267.16% |
| 2019 | -11.66 | 16.64% |
| 2018 | -9.99 | -48.06% |
| 2017 | -19.24 | 80.88% |
| 2016 | -10.64 | 16.86% |
| 2015 | -9.10 | 48.53% |
| 2014 | -6.13 | -48.09% |
| 2013 | -11.81 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -123.79% |
US
|
|
| -28.36 | -76.56% |
US
|
|
| -24.57 | -79.70% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -125.07% |
NL
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.